Data Management Header Image

 





Data Management
Transform Data into Strategic Assets for Discovery, Collaboration, and AI
5/20/2026 - May 21, 2026
The Data Management track showcases how life-science organizations are modernizing their research data foundations to support FAIR principles, AI readiness, and enterprise-scale scientific operations. The 2026 program emphasizes practical, production-level strategies—spanning metadata automation, cloud-native data platforms, data product architectures, knowledge-graph–enabled enrichment, and governance models that ensure trust, compliance, and interoperability. Speakers will share real-world transformations across R&D, translational science, and clinical research, highlighting how robust data infrastructure accelerates discovery, improves decision-making, and reduces operational burden. Designed for leaders in data strategy, research informatics, R&D IT, compliance, and digital transformation, this track delivers the frameworks and tools needed to turn fragmented data into reusable, AI-ready assets and scalable enterprise knowledge.

Tuesday, May 19

Recommended Pre-Conference Workshops and Symposia*

On Tuesday, May 19, 2026, Cambridge Healthtech Institute is pleased to offer six pre-conference Workshops scheduled across two time slots (9:00 am–12:00 pm and 1:15–4:15 pm) and three Symposia from 8:30 am–3:45 pm. All are designed to be instructional, interactive, and provide in-depth information on a specific topic. They allow for one-on-one interaction and provide a great way to explain more technical aspects that would otherwise not be covered during the main conference tracks that take place Wednesday–Thursday.

*Separate registration required. Additional details:

Symposia: www.bio-itworldexpo.com/symposia

Workshops: www.bio-itworldexpo.com/workshops

PLENARY KEYNOTE PROGRAM

Grab Your Seat! 25th Annual Golden Ticket Prize Giveaway & Organizer’s Remarks*

Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute

*Must be present to win.

Welcome Remarks from the City of Boston and the Office of Mayor Michelle Wu

Photo of Donald Wright, Interim Chief, Economic Opportunity & Inclusion Cabinet, City of Boston , Interim Chief , Economic Opportunity & Inclusion Cabinet , City of Boston
Donald Wright, Interim Chief, Economic Opportunity & Inclusion Cabinet, City of Boston , Interim Chief , Economic Opportunity & Inclusion Cabinet , City of Boston

PLENARY KEYNOTE PRESENTATION:
Rare Conversations: Explorations of the Research, Funding, and Advocacy for Rare Diseases

Photo of Thomas Bartlett, Ambassador, MG Uniter Myasthenia Gravis, Amgen , Patient Ambassador - MG Uniter Myasthenia Gravis , Patient Advocate , Amgen
Thomas Bartlett, Ambassador, MG Uniter Myasthenia Gravis, Amgen , Patient Ambassador - MG Uniter Myasthenia Gravis , Patient Advocate , Amgen
Photo of Catherine Brownstein, PhD, Manager, Molecular Genomics Core Facility, Boston Children's Hospital; Scientific Director, Manton Center for Orphan Disease Research Gene Discovery Core; Assistant Professor, Harvard Medical School , Assistant Professor , Boston Children's Hospital
Catherine Brownstein, PhD, Manager, Molecular Genomics Core Facility, Boston Children's Hospital; Scientific Director, Manton Center for Orphan Disease Research Gene Discovery Core; Assistant Professor, Harvard Medical School , Assistant Professor , Boston Children's Hospital
Photo of Morgan Cheatham, MD, Partner, Head of Healthcare & Life Sciences, Breyer Capital , Partner, Head of Healthcare & Life Sciences , Breyer Capital
Morgan Cheatham, MD, Partner, Head of Healthcare & Life Sciences, Breyer Capital , Partner, Head of Healthcare & Life Sciences , Breyer Capital
Photo of Sebastien Lefebvre, Head of Technology, Data and AI, Aurelis Insights , Head of Technology, Data and AI , Aurelis Insights
Sebastien Lefebvre, Head of Technology, Data and AI, Aurelis Insights , Head of Technology, Data and AI , Aurelis Insights
Photo of Dylan V. Livingston, Founder and President, The Alliance for Longevity Initiatives (A4LI) , Founder and President , The Alliance for Longevity Initiatives (A4LI)
Dylan V. Livingston, Founder and President, The Alliance for Longevity Initiatives (A4LI) , Founder and President , The Alliance for Longevity Initiatives (A4LI)
Photo of William Van Etten, PhD, Co-Founder, CEO & Principal Scientist, StarfleetBio , Co-Founder, CEO & Principal Scientist , StarfleetBio
William Van Etten, PhD, Co-Founder, CEO & Principal Scientist, StarfleetBio , Co-Founder, CEO & Principal Scientist , StarfleetBio
Photo of Susan J. Ward, PhD, Founder & Executive Director, cTAP , Founder & Executive Director , cTAP
Susan J. Ward, PhD, Founder & Executive Director, cTAP , Founder & Executive Director , cTAP

In a unique plenary series of intimate conversations, we will explore the models, drivers, and challenges facing rare disease research. By uniting leaders in precision medicine, bioinformatics, national rare-disease infrastructure, and real-world legislative advocacy, we will give attendees an expansive, cross-disciplinary view of what’s required to deliver faster, more accurate, and more equitable rare-disease cures.

Welcome Reception & 25th Anniversary Celebration in the Exhibit Hall with Poster Viewing

The Bio-IT Kickoff Reception is a reunion, reconnect with friends, explore cutting-edge research, and celebrate innovation! This year, join us in celebrating the 25th Anniversary of Bio-IT World Conference & Expo with cake and champagne as we mark a quarter century of advancing science and technology. Enjoy poster presentations, networking, and vote for the Best of Show and Poster awards.

Close of Day

Wednesday, May 20

Bio-IT World’s 5K Rise and Shine Fun Run! (Sponsorship Opportunities Available)

RUN COORDINATORS:
Bridget Kotelly, Senior Conference Director, Cambridge Healthtech Institute
Eileen Murphy, Conference Producer, Cambridge Healthtech Institute

Lace up and join Bio-IT’s Coordinators for the Fun Run on Wednesday, May 20! Sprint, jog, walk, or talk-your-way-through—ALL abilities are welcome. This informal event is all about getting moving together. Full details to come…just don’t forget your sneakers!

Registration and Morning Coffee

PLENARY KEYNOTE PROGRAM

Grab Your Seat! 25th Annual Golden Ticket Prize Giveaway & Organizer’s Remarks*

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News , Editorial Dir , Bio-IT World

*Must be present to win.

PLENARY KEYNOTE PRESENTATION:
The Collaboration Breakthrough: How Federated Learning Is Rewriting the Rules of Drug Discovery

Photo of Mohammed AlQuraishi, PhD, Assistant Professor, Systems Biology, Columbia University , Assistant Professor , Systems Biology , Columbia University
Mohammed AlQuraishi, PhD, Assistant Professor, Systems Biology, Columbia University , Assistant Professor , Systems Biology , Columbia University
Photo of Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company , Sr. Director - Ecosystem Growth and Contributor Partnerships , Eli Lilly and Company
Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company , Sr. Director - Ecosystem Growth and Contributor Partnerships , Eli Lilly and Company
Photo of José-Tomás Prieto, PhD, Director of AI Programs, Apheris , Director of AI Programs , Apheris
José-Tomás Prieto, PhD, Director of AI Programs, Apheris , Director of AI Programs , Apheris
Photo of Woody Sherman, PhD, Founder and Chief Innovation Officer, PsiThera , Founder and Chief Innovation Officer , PsiThera
Woody Sherman, PhD, Founder and Chief Innovation Officer, PsiThera , Founder and Chief Innovation Officer , PsiThera
Photo of Christina Taylor, PhD, Senior Science Fellow and Computational Molecular Design Lead, Bayer , Senior Science Fellow and Computational Molecular Design Lead , Bayer
Christina Taylor, PhD, Senior Science Fellow and Computational Molecular Design Lead, Bayer , Senior Science Fellow and Computational Molecular Design Lead , Bayer
Photo of Arman Zaribafiyan, PhD, Head of Strategic Alliances, AI Simulation, SandboxAQ , Head of Strategic Alliances, AI Simulation , SandboxAQ
Arman Zaribafiyan, PhD, Head of Strategic Alliances, AI Simulation, SandboxAQ , Head of Strategic Alliances, AI Simulation , SandboxAQ

The pharmaceutical industry sits on a collective treasure trove of proprietary structural biology data, yet competitive concerns have historically prevented the data sharing necessary to train the most powerful AI models for drug discovery. Federated learning is changing this paradigm, enabling biopharma companies to collaborate on AI model training while keeping sensitive data secure and confidential. This plenary session explores the groundbreaking AI Structural Biology (AISB) Network, where industry leaders are pooling proprietary protein-ligand structure data to collaboratively train OpenFold3, an AI model designed to predict molecular interactions with precision approaching X-ray crystallography. Through the federated computing platform, thousands of experimentally determined protein–small molecule structures remain securely at their original locations while contributing to a shared learning framework that no single organization could achieve alone. This session reveals how federated learning solves the industry's most persistent challenge: unlocking collective intelligence while protecting intellectual property. ​Attendees will hear directly from consortium leaders about: 

  • The technical architecture enabling privacy-preserving collaborative AI training across competing organizations 
  • Real-world implementation of federated learning platforms and computational governance frameworks 
  • Strategic rationale for industry collaboration: why sharing model training beats going it alone 
  • Impact and outcomes from early OpenFold3 results in predicting binding affinities and accelerating small molecule discovery 
  • The future of collaborative AI in biopharma, from structural biology to clinical development

Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

Start your morning with coffee, connections, and cutting-edge research! Enjoy poster presentations, network in the Exhibit Hall, vote for awards, and a chance at a fabulous raffle prize!

BUILDING THE TRUST ARCHITECTURE: FROM PETABYTES TO IMMUTABLE PLATFORMS

Organizer's Welcome Remarks

Robin Lockett, Room Operations Lead, Cambridge Healthtech Institute , Contractor , Cambridge Healthtech Institute

Chairperson's Remarks: Building the Trust Architecture from Petabytes to Immutable Platforms

Ted Slater, Global Head, Knowledge Engineering and Data Advisory, EPAM Systems, Inc. , Global Head, Knowledge Engineering and Data Advisory , EPAM Systems Inc

Using robust data architecture to turn fragmented, siloed data into reusable, AI-ready data products that actually work at enterprise scale.

From Archive to Ecosystem: Architecting a Petabyte-Scale Biomedical Platform for Sustainable and FAIR Discovery

Photo of J. Rodney Brister, PhD, Acting Program Head, Sequence Read Archive, NCBI, NLM, NIH , Acting Program Head, Sequence Read Archive , NCBI, NLM, NIH
J. Rodney Brister, PhD, Acting Program Head, Sequence Read Archive, NCBI, NLM, NIH , Acting Program Head, Sequence Read Archive , NCBI, NLM, NIH

The Sequence Read Archive is the world’s largest open-access repository of genetic data generated by high-throughput sequencing technologies. This presentation provides an initial report from our journey to transform this petabyte-scale data repository into a sustainable, cloud-agnostic resource – fully integrated into the biomedical research ecosystem. We describe strategies for modernizing a production system, balancing ongoing operations while progressively implementing a standards-based framework that supports reliability, governance, and FAIR data practices.

Building Bridges: Developing the Omics Commons at AbbVie

Photo of Brett W. Engelmann, PhD, Senior Data Scientist, Information Research, AbbVie, Inc. , Sr Data Scientist , Information Research , AbbVie Inc
Brett W. Engelmann, PhD, Senior Data Scientist, Information Research, AbbVie, Inc. , Sr Data Scientist , Information Research , AbbVie Inc

This talk will describe the evolution of AbbVie's omics data strategy from a disparate collection of siloed, single-purpose tools into a unified, commons-based approach. Today, AbbVie is leveraging a common omic data model, ontologies, and visualization tools to achieve FAIR principles and impact the pipeline. The omics commons establishes a better way forward for archiving, re-analyzing, meta-analyzing, and discovering omic data.

Operationalizing LLM-Driven Data Curation for Oncology Clinical Trials

Photo of Karnaditya (Karan) Rana, Associate Director, Clinical Data Management, Tempus AI , Associate Director, Clinical Data Management , Data Services , Tempus AI
Karnaditya (Karan) Rana, Associate Director, Clinical Data Management, Tempus AI , Associate Director, Clinical Data Management , Data Services , Tempus AI

Large Language Models are transforming oncology clinical trial data curation by enabling scalable extraction of structured variables from unstructured EHR data. This presentation examines how LLMs can be operationalized within clinical data pipelines, integrating metadata standardization, validation frameworks, and human-in-the-loop quality control. Case studies demonstrate high concordance with manual abstraction while reducing time and cost. Attendees will gain practical strategies for deploying AI-driven curation systems that improve data quality, interoperability, and trial readiness.

Transition to Lunch

Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

Bio-IT's hall is bigger than ever; one break won’t cut it! Enjoy dessert and coffee after lunch, explore booths and posters, vote for awards, and participate in our raffle for a chance to win a prize!

UNLEASHING INTELLIGENCE: FROM DATA STEWARDSHIP TO GENAI ACCELERATION

Chairperson's Remarks

Grant Stephen, CEO & Co-Founder, bPrescient, Inc. , CEO & Co-Founder , bPrescient Inc

Data Stewardship in Pharmaceutical Research

Photo of Michael Farnum, PhD, Director of Research Data Stewardship, GSK , Director of Research Data Stewardship , Research Data Office , GSK
Michael Farnum, PhD, Director of Research Data Stewardship, GSK , Director of Research Data Stewardship , Research Data Office , GSK

This presentation will connect principals of quality data to initiatives ongoing at GSK to increase the speed, confidence, and compliance of work to bring medicines to patients. Applications of metadata collection and curation, data modeling, and the use of ontologies to drive data integration will be shown to increase the scope of data available to compute.

DTS Portal: GenAI-Powered Biomarker Data Transfers with Vendors

Photo of Mahesh Nawade, Director, Research Data Engineering & Operations, Business Insights & Technology, Bristol Myers Squibb Co. , Dir Research Data Engineering & Operations , Business Insights & Technology , Bristol Myers Squibb Co
Mahesh Nawade, Director, Research Data Engineering & Operations, Business Insights & Technology, Bristol Myers Squibb Co. , Dir Research Data Engineering & Operations , Business Insights & Technology , Bristol Myers Squibb Co
Photo of Ranga Rajan, PhD, Strategy Insights & Planning Consultant, ZS Associates , Biomedical R&D Consultant , ZS Associates
Ranga Rajan, PhD, Strategy Insights & Planning Consultant, ZS Associates , Biomedical R&D Consultant , ZS Associates

The DTS Portal is a transformative solution for biomarker data operations, designed to address the persistent bottlenecks in onboarding external vendor data. In pharmaceutical research, creating Data Transfer Specifications (DTSes) between sponsors like BMS and external vendors is often a slow, manual, and error-prone process. The DTS Portal replaces this with a centralized, user-friendly interface that automates document creation, version control, and stakeholder collaboration.

Findit—Empowering You to Find What Matters

Photo of Rajat Sapru, Associate Principal, ZS Associates , Associate Principal , ZS Associates
Rajat Sapru, Associate Principal, ZS Associates , Associate Principal , ZS Associates
Photo of Kinny Trivedi, Master Data Management, Innovative Medicine Technology, Johnson & Johnson , Head of Master Data Mgmt , Innovative Medicine Technology , Johnson & Johnson
Kinny Trivedi, Master Data Management, Innovative Medicine Technology, Johnson & Johnson , Head of Master Data Mgmt , Innovative Medicine Technology , Johnson & Johnson

This presentation will illustrate how AI-enabled data discovery is reshaping clinical development by making assets easier to find, trust, and apply. Traditional methods—hampered by fragmented systems, inaccurate metadata, and low-relevance results—limit efficiency and confidence. By combining semantic intelligence, contextualized search, and adaptive metadata enrichment, sponsors can break silos, accelerate insights, and enable confident decisions, driving a step-change in productivity, quality, and speed across the value chain.

Best of Show Awards Reception in the Exhibit Hall with Poster Viewing

Unwind with colleagues at our lively reception! Explore posters, vote for the best, network with exhibitors, enjoy a drink, and try to win a raffle prize. Celebrate Best of Show winners!

Close of Day

Thursday, May 21

Registration Open

Continental Breakfast with Breakout Discussions

CONTINENTAL BREAKFAST WITH BREAKOUT DISCUSSIONS (IN-PERSON ONLY)

Connect & Collaborate: Breakfast Networking Roundtables (Sponsorship Opportunities Available)

Start the day with small-group roundtable discussions designed to spark collaboration and exchange insights across the Bio-IT community. Attendees join themed tables—spanning AI, data ecosystems, foundational models, and more—for focused, peer-driven discussions that foster problem-solving, connection, and cross-functional perspectives ahead of the plenary keynote.

IN-PERSON ONLY –
TABLE 1: Knowledge Graphs

Tom Plasterer, PhD, CEO & Co-Founder, Knowledge3 , CEO & Founder , BioPharmaceuticals R&D , Knowledge3 LLC

  • How are knowledge graphs supporting reliable scientific intelligence
  • Lessons from early deployments
  • Remaining challenges and barriers to scale​

IN-PERSON ONLY –
TABLE 2: From Molecules to Qubits: A Collaborative Conversation on Pharma’s Quantum Future

Christopher Bishop, Chief Reinvention Officer, Improvising Careers , Podcast host , Improvising Careers

  • Learn how leading global pharma companies are applying quantum principles to real-world research. 
  • Discover the quantum companies transforming traditional processes around drug development and drug discovery.
  • Discuss how quantum, along with HPC and AI, is poised to help researchers tackle historically intractable problems and potentially find new treatments for diseases like cancer, Alzheimer’s, and diabetes.​

IN-PERSON ONLY –
TABLE 3: From AI Tools to Autonomous Discovery: Are We Ready for Agentic AI in Drug Discovery?

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India , Professor and Director , Centre for AI in Medicine , Vinayaka Mission's Research Foundation

  • Where are we today? Are AI tools truly integrated into workflows, or still operating in silos?
  • What changes with agents? How do LLM-based agents shift drug discovery from prediction to decision-making?
  • What is blocking autonomy? Data quality, validation, trust, or organizational readiness for AI-driven discovery?​

IN-PERSON ONLY –
TABLE 4: Bridging Tech Transfer and Industry: Unlocking Real Collaboration at Bio-IT

Nancy Wetherbee, Director Commercialization, Research Innovation Center, Northeastern University , Dir Commercialization , Research Innovation Ctr , Northeastern Univ

  • Where are the highest-value collaboration opportunities between academia/TTOs and industry (biopharma, startups, AI/data, investors), and what makes them actually work?
  • What types of partnerships are most effective in practice (licensing, co-development, startup creation, sponsored research), and how do both sides evaluate quality and fit quickly?
  • What specific formats, access points, or structures at the Bio-IT event would actually drive follow-up, partnerships, and deal-making?

IN-PERSON ONLY –
TABLE 5: Supporting Innovation While Managing Risk: The CIO’s Dilemma in AI-Driven R&D

Chris Dwan, Fractional CIO, Triveni Bio , Independent Consultant , Dwan, LLC

  • How do CIOs enable rapid AI and data innovation without breaking governance, compliance, or data integrity frameworks?
  • What separates pilot-stage innovation from scalable, production-grade systems? Where do most organizations fail?
  • How do leaders manage emerging risks (model bias, data provenance, regulatory exposure) while still pushing competitive advantage?

IN-PERSON ONLY –
TABLE 6: Real-World Data and Evidence: Unlocking Value Beyond Clinical Trials

Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC , Managing Dir & Co Founder , IPQ Analytics LLC

  • How real-world data is being used alongside clinical and experimental data
  • Challenges in standardization, access, and regulatory acceptance
  • Opportunities to improve outcomes, access, and long-term patient insights

IN-PERSON ONLY –
TABLE 7: Beyond Data Management: Why AI Fails without Institutional Memory in Life Sciences

Alexandra Brocato, CEO & Co-Founder, Beakr, Inc. , CEO & Co Founder , Beakr Inc

  • Why critical experimental knowledge is lost across ELNs, LIMS, and siloed teams, and the cost of reinventing work 
  • How structured experimental memory makes past decisions, failures, and context reusable across teams
  • How organizations can make scientific knowledge reusable for both humans and AI

IN-PERSON ONLY –
TABLE 8: Intellectual Property in Biotech: Strategy, Patents, and Trademarks

Elizabeth F. Jackson, Acting Director, Northeast Regional Outreach Office, U.S. Patent and Trademark Office , Acting Director , Northeast Regional Outreach Office , U.S. Patent and Trademark Office

  • How to think strategically about IP early in biotech and AI-driven research
  • Common pitfalls in patent and trademark applications and how to avoid them
  • Navigating ownership, protection, and commercialization of innovations

IN-PERSON ONLY –
TABLE 9: Are Bioinformatics Workflows Broken? Rethinking Pipelines in the Age of No-Code and AI

Daniel Clarke, Biomedical Software Developer, Icahn School of Medicine at Mount Sinai , Biomedical Software Developer , Icahn School of Medicine at Mount Sinai

  • Why do current workflow systems fail most scientists in practice? 
  • Can no-code and AI-driven workflows meet standards for reproducibility, validation, and clinical readiness? 
  • What would a “production-ready” workflow ecosystem actually look like across teams and organizations?

IN-PERSON ONLY –
TABLE 10: Data Readiness for AI: Why Most AI Programs Fail Before They Start

Bahador Marzban, PhD, Principal Data Scientist, Innovative Medicine R&D, Johnson & Johnson , Principal Data Scientist , Innovative Medicine R&D , Johnson & Johnson

  • The gap between AI ambition and the reality of data foundations, platforms, and operating models
  • What “AI‑ready data” actually means in practice—beyond pilots, dashboards, and proofs of concept 
  • Where AI initiatives most often break down: data integration, data quality, metadata, and governance at scale​

PLENARY KEYNOTE PROGRAM

Grab Your Seat! 25th Annual Golden Ticket Prize Giveaway & Organizer’s Remarks*

Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute

*Must be present to win.

Bio-IT World 2026 Innovative Practices Awards Ceremony (Winners Announced)

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News , Editorial Dir , Bio-IT World

Since 2003, Bio-IT World’s Innovative Practices Awards have recognized outstanding technology innovation advancing life sciences research. The 2026 winners highlight excellence in open science, patient advocacy, global data access, and real-world AI through collaborations involving Arizona State University and Starfish Storage, CareDx, ASAP Discovery Consortium, and Novartis with Genedata AG. Together, these projects illustrate the modern R&D data lifecycle, from unlocking legacy data to enabling collaboration and driving clinical decision-making.

Bio-IT World 2026 Emerging Innovator Award—NEW (Winner Announced)

Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News , Editorial Dir , Bio-IT World

The Emerging Innovator Award recognizes one exceptional early-career researcher advancing the future of life sciences through breakthrough work in biomedical data, computational methods, or technology-enabled discovery. The 2026 awardee will deliver a 20-minute plenary keynote at Bio-IT World, highlighting the impact of their research and the forward-looking direction of their work. 

EMERGING INNOVATOR AWARD PRESENTATION: Scalable Connectomics for AI-Ready Brain Data

Photo of Ons M'Saad, PhD, Co-Founder & CEO, panluminate Inc. , Co-Founder & CEO , panluminate Inc.
Ons M'Saad, PhD, Co-Founder & CEO, panluminate Inc. , Co-Founder & CEO , panluminate Inc.

Mapping the brain at synaptic resolution—connectomics—could transform neuroscience, medicine, and AI. Until now, the field has depended on electron microscopy: slow, expensive, difficult to scale, and limited to structure alone. Dr. Ons M’Saad presents a new optical approach that adds molecular context to large-scale brain maps, opening new ways to study neurodegenerative disease and inform more biologically grounded AI.

PLENARY KEYNOTE PRESENTATION:
Generative AI across Drug Discovery Tasks

Photo of Jeremy L. Jenkins, PhD, US Head, Discovery Sciences, Novartis BioMedical Research , US Head , Discovery Sciences , Novartis BioMedical Research
Jeremy L. Jenkins, PhD, US Head, Discovery Sciences, Novartis BioMedical Research , US Head , Discovery Sciences , Novartis BioMedical Research

Many steps in drug discovery are informed by large-scale biological and chemical data, from genomics to the chemical universe, to phenotypic cell profiling. Generative-ML models are increasingly being deployed across these domains, including single-cell foundation models for target discovery, generative chemistry for rapid ligand design, and transfer learning to accelerate image analysis. Practical applications of generative AI in early drug discovery will be described, including simulated functional-genomics screens with in silico perturbations; compound design conditioned on protein pockets; and in silico-labeling approaches that replace traditional image staining. Together, these advances illustrate how generative AI is transforming how drug discovery research is conducted.

Coffee Break in the Exhibit Hall with Poster Competition Winners Announced (Sponsorship Opportunity Available)

Bio-IT is all about connections! Explore booths, award-winning posters, and network with clients, colleagues, and exhibitors. Grab coffee, build relationships, and stay for a chance to win a raffle prize!

INNOVATIVE PRACTICES AWARD WINNER PRESENTATIONS: BEST PRACTICES IN TECHNOLOGY INNOVATION

Organizer's Remarks

Robin Lockett, Room Operations Lead, Cambridge Healthtech Institute , Contractor , Cambridge Healthtech Institute

Chairperson's Remarks

Chris Mueller, PhD, Principal Consultant, Boulder BioComputing, Inc. , Principal Consultant , Boulder BioComputing Inc

Innovative Practices Award Winner Presentations: Excellence in Technological Innovation

Photo of Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute
Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute

Since 2003, Bio-IT World has hosted an elite awards program with the goal of highlighting outstanding examples of how technology innovations and strategic initiatives are being applied to advance life sciences research. The 2026 Innovative Practices Awards winners represent excellence in innovation in the areas of open science, patient advocacy, global data access, and real-world AI. The winning entries include collaborations between Arizona State University with Starfish Storage; CareDx; ASAP Discovery Consortium; and Novartis with Genedata AG. These four award-winning examples show the full lifecycle of data in modern R&D, from unlocking legacy data, to building enterprise platforms, to enabling open collaboration, and ultimately driving clinical decision-making.

From Unsearchable Archive to Self-Service Knowledge Platform: How ASU Transformed 20 Years of Indigenous Health Imaging Data (Innovative Practices Winner)

Photo of Ari E. Berman, Chief Science Officer, Starfish Storage , Chief Science Officer , Starfish Storage Corp.
Ari E. Berman, Chief Science Officer, Starfish Storage , Chief Science Officer , Starfish Storage Corp.

For over two decades, a Bolivian hospital has collected CT scans of the Tsimane indigenous population as part of Arizona State University’s Tsimane Health and Life History Project, creating a unique longitudinal archive for studying healthy aging. But the archive was functionally unsearchable. Inconsistent Digital Imaging and Communications in Medicine (DICOM) metadata across more than 20 years of scanner evolution meant every researcher request required days of manual investigation by ASU’s IT team.

ASU’s Center for Evolution and Medicine partnered with Starfish Storage to transform this archive into a self-service, consent-governed knowledge platform. Using metadata-driven virtualization, researchers now discover and access imaging data in minutes instead of weeks. Policy-based access controls enforce Tsimane community consent agreements automatically. The deployment eliminated hours of weekly manual curation that had become unsustainable as collaboration scaled, while enabling dozens of global collaborators to work independently.

Real-World AI Award: Novartis Reimagines CMC with AI-Native Data Platform (Innovative Practices Winner)

Photo of Ganga Kalidindi, Global Head, TRD Data & AI, Novartis , Global Head TRD Data & AI , Technical Research & Development , Novartis Pharmaceuticals Corporation
Ganga Kalidindi, Global Head, TRD Data & AI, Novartis , Global Head TRD Data & AI , Technical Research & Development , Novartis Pharmaceuticals Corporation

As therapeutic modalities grow more complex and regulatory scrutiny becomes increasingly data-driven, traditional document-centric CMC operating models are no longer sufficient. To address this challenge, Novartis Technical R&D organization implemented an interoperable, AI-native, GxP-enabled data platform that transforms fragmented information into trusted, reusable data assets. This foundation enables in silico experimentation, modelling and simulations, process monitoring and predictive risk assessment, empowering teams to anticipate and mitigate risks earlier and accelerate readiness for regulatory milestones. These capabilities have the potential to eliminate months‑long development delays and generate multimillion‑dollar per‑site savings, while extending beyond near‑term efficiency to support better decision‑making, scalable quality and compliance, and deeper scientific insight across the CMC portfolio. The platform, developed collaboratively with Genedata, has evolved for use beyond the original implementation into an off-the-shelf product for biopharma CMC.

ASAP Discovery Consortium—Data Sharing for Open Science (Innovative Practices Award Winner)

Photo of Nick Lynch, PhD, Founder & CTO, Curlew Research , Founder & CTO , Curlew Research
Nick Lynch, PhD, Founder & CTO, Curlew Research , Founder & CTO , Curlew Research

The AI-driven Structure-enabled Antiviral Platform (ASAP) is an open-science consortium developing oral, clinic-ready therapeutics for pandemic-potential RNA viruses, including coronaviruses, flaviviruses, and picornaviruses. Funded by NIAID investment, ASAP leverages the cost-efficient COVID Moonshot model to bridge the "preclinical valley of death". By integrating AI/ML, automated structural biology at Diamond Light Source, the platform has delivered a pre-clinical candidate in 2025, 8 hit to lead candidates, and ten resistance-robust targets. 

ASAP treats all outputs—including structural data, assay protocols, and chemical matter—as "first-class research products" shared via FAIR data repositories (ChEMBL, PDB, Protocols.io, AddGene, Github). Notably, in 2023, the consortium contributed 6% of all new X-ray structures to the Protein Data Bank. A recent community blind challenge with Polaris and OpenADMET further demonstrated the platform's utility by benchmarking computational methods against real-world lead-optimisation data, advancing reproducible, high-impact drug discovery.

AlloSure Plus (Innovative Practices Award Winner)

Photo of Jing Huang, PhD, Chief Data & AI Officer, CareDx, Inc. , Chief Data & AI Officer , CareDx Inc
Jing Huang, PhD, Chief Data & AI Officer, CareDx, Inc. , Chief Data & AI Officer , CareDx Inc

AlloSure Plus is a CareDx innovation project advancing organ transplant surveillance through the integration of molecular diagnostics, clinical data, and artificial intelligence (AI). The project culminated in the development of an AI‑enabled risk‑prediction framework that combines AlloSure Kidney donor‑derived cell‑free DNA (dd‑cfDNA) analysis with routinely collected clinical and laboratory parameters to deliver a personalized assessment of kidney allograft rejection risk. 

Designed to address the long‑standing challenge of late and non‑specific rejection detection, AlloSure Plus demonstrates how data integration and machine learning can improve the timing, accuracy, and confidence of clinical decision‑making. The outcome is a scalable, validated model that supports earlier intervention, reduces reliance on invasive biopsies, and enables more individualized patient management. AlloSure Plus exemplifies how applied AI and real‑world clinical data can be translated into actionable insights that improve transplant outcomes and elevate standards of care.

Q&A with Innovative Practices Award Speakers

Photo of Ari E. Berman, Chief Science Officer, Starfish Storage , Chief Science Officer , Starfish Storage Corp.
Ari E. Berman, Chief Science Officer, Starfish Storage , Chief Science Officer , Starfish Storage Corp.
Photo of Jing Huang, PhD, Chief Data & AI Officer, CareDx, Inc. , Chief Data & AI Officer , CareDx Inc
Jing Huang, PhD, Chief Data & AI Officer, CareDx, Inc. , Chief Data & AI Officer , CareDx Inc
Photo of Ganga Kalidindi, Global Head, TRD Data & AI, Novartis , Global Head TRD Data & AI , Technical Research & Development , Novartis Pharmaceuticals Corporation
Ganga Kalidindi, Global Head, TRD Data & AI, Novartis , Global Head TRD Data & AI , Technical Research & Development , Novartis Pharmaceuticals Corporation
Photo of Nick Lynch, PhD, Founder & CTO, Curlew Research , Founder & CTO , Curlew Research
Nick Lynch, PhD, Founder & CTO, Curlew Research , Founder & CTO , Curlew Research
Photo of Chris Mueller, PhD, Principal Consultant, Boulder BioComputing, Inc. , Principal Consultant , Boulder BioComputing Inc
Chris Mueller, PhD, Principal Consultant, Boulder BioComputing, Inc. , Principal Consultant , Boulder BioComputing Inc

STRUCTURING R&D DATA FOR AI-READY DECISION-MAKING

The Two-Year Journey to an AI-Ready Research Data Mesh: Scaling a Data Product Factory across 10M+ Molecules

Photo of James Ewen, Director & Product Owner, R&D Business Insights & Technology, Bristol Myers Squibb Co. , Dir & Product Owner , R&D Business Insights & Technology , Bristol Myers Squibb Co
James Ewen, Director & Product Owner, R&D Business Insights & Technology, Bristol Myers Squibb Co. , Dir & Product Owner , R&D Business Insights & Technology , Bristol Myers Squibb Co
Photo of Ashlyn Lalk, Senior Manager Business Analysis, Bristol Myers Squibb , Senior Manager Business Analysis , Bristol Myers Squibb
Ashlyn Lalk, Senior Manager Business Analysis, Bristol Myers Squibb , Senior Manager Business Analysis , Bristol Myers Squibb

In two years, BMS transformed siloed research data into an AI-ready discovery engine—building a governed ecosystem of reusable data products across small- and large-molecule pipelines. This session unpacks the architecture, patterns, and organizational moves behind a data product factory built on FAIR principles, delivering real-time visibility across 10M+ compound journeys, accelerated predictive modeling, and emerging agentic AI workflows. Walk away with a practical blueprint and hard-won lessons.

Structured Intelligence for Complex Processes in Biopharma

Photo of Eric Neumann, PhD, Co-founder and Chief Knowledge and Intelligence Officer (CKIO), IQUrium , Co-founder and Chief Knowledge and Intelligence Officer , IQUrium
Eric Neumann, PhD, Co-founder and Chief Knowledge and Intelligence Officer (CKIO), IQUrium , Co-founder and Chief Knowledge and Intelligence Officer , IQUrium

There is an urgent need in biopharma to support the handling of complex data generated across diverse processes, often spanning varying and extended timeframes. Furthermore, it is increasingly critical this information be structured in a way that’s readily usable by AI tools. IQUrium is addressing this with a set of powerful technologies that organize all data using a Causal Context backbone. In addition to structuring data, our approach also enables a unique and practical way to combine semantics (ontologies) without resorting to upper ontologies or unconventional mergers. This allows the optimization of biotech workflows and discovery of new process insights.

Session Break and Transition to Lunch

Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

Feeling tired? Recharge during the final Networking Exhibit Hall break! Visit booths, explore posters, connect with peers, and turn in your Game Cards for a chance to win a raffle prize.

TRENDS FROM THE TRENCHES: BRIDGING TRADITIONAL INSIGHTS WITH INNOVATIVE ADVANCEMENTS

Chairperson's Remarks

Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute

For 20 years, Trends from the Trenches has been Bio-IT World’s unscripted pulse check, offering candid, insider perspectives on what works, what fails, and what’s pure hype in scientific computing. As the field evolved, the session broadened to reflect the real operational challenges and breakthroughs shaping R&D. For 2026, the format evolves again: a focused, credibility-driven keynote paired with a community-powered unconference built from attendee input. The result is a forum for late-breaking insights, grounded realities, forward-looking perspectives, and practical solutions you won’t find in vendor decks, marketing summaries, or any LLM. It leaves participants energized by the collective intelligence in the room and inspired by the emerging possibilities shaping the future of life-science computing.

From 20 Years of Trends to the Next Era of Digital R&D

Photo of Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute
Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute , Executive Event Director , Cambridge Healthtech Institute

This presentation frames the industry’s next chapter by tracing how Trends from the Trenches has shaped digital R&D for two decades and by spotlighting the forces redefining scientific computing today: AI–HPC convergence, modality-driven compute, multimodal data, and rising expectations for speed, interoperability, and trust. Remarks set the foundation for a forward-looking exploration of where digital biology and computational innovation are heading next.

Remarks & Introduction

Photo of Chris Dagdigian, Co-Founder and Senior Director, The BioTeam, Inc.; Founder, Trends from the Trenches , Co-founder and Senior Director , BioTeam Inc
Chris Dagdigian, Co-Founder and Senior Director, The BioTeam, Inc.; Founder, Trends from the Trenches , Co-founder and Senior Director , BioTeam Inc

FEATURED TALK: The Hard Truth about Digital R&D: Patterns, Pitfalls, and the Next Wave of Innovation

Photo of Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science , Founder & CEO , Diamond Age Data Science
Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science , Founder & CEO , Diamond Age Data Science

This presentation delivers a candid, comprehensive assessment of the forces reshaping scientific computing and digital R&D. Eleanor examines the technologies, platforms, modalities, and market dynamics that are truly driving change—highlighting what’s working, what’s stalling, and what’s losing relevance. She synthesizes emerging patterns across AI, data platforms, workflow orchestration, multimodal analytics, and new therapeutic and diagnostic directions, while calling out persistent bottlenecks and architectural missteps slowing progress. The result is a grounded, evidence-based view of where the field is heading and which strategies will matter most in the next cycle of innovation.

Community Unconference: Live Problems, Live Solutions

Photo of Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News , Editorial Dir , Bio-IT World
Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News , Editorial Dir , Bio-IT World

This session features a structured, participatory unconference built around topics sourced from Bio-IT event attendees during the conference week. A working group synthesizes all submissions Wednesday evening into a small set of high-value discussion themes. The facilitator guides the room through rapid-fire exchanges, micro-debates, and collaborative problem-solving focused on operational realities in AI, computing, data engineering, and scientific software. The goal is to surface patterns, stress-test ideas, and extract practical solutions emerging across the community—creating an annual, crowd-generated state-of-the-field snapshot that only this session can produce.

Close of Conference


Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure